Ebola in Congo, the Clinical Trial That Could Change Everything

Introduction: one first patient, one cautious hope

A quiet announcement with heavy implications

On July 2, 2026, the World Health Organization confirmed that a first patient had just been enrolled in a clinical trial designed to test two potential treatments against the Bundibugyo strain of the Ebola virus, behind an outbreak that has been hitting eastern Democratic Republic of Congo since May. This moment, described by WHO Director-General Tedros Adhanom Ghebreyesus as a decisive milestone, is no media stunt: it is the result of weeks of scientific and logistical preparation.

To understand why this launch matters, one first has to grasp the scale of the situation on the ground. According to data published by the European Centre for Disease Prevention and Control, the DRC had, as of July 2, 2026, a total of 1,460 confirmed cases and 452 deaths linked to this outbreak, with 213 people having recovered. These numbers are a cold clinical reminder that every week without an approved treatment costs lives.

Why this strain defeats existing tools

The Bundibugyo strain is less familiar to the public than the Zaire strain, responsible for the massive West African outbreaks of 2014 and the one in eastern Congo in 2018–2020. Yet it poses a very concrete problem: no approved vaccine and no approved treatment currently exists against it, unlike the Zaire strain, for which the Ervebo vaccine and certain monoclonal antibodies have already proven effective.

This is precisely the gap the trial launched this week is trying to close. In a world saturated with bad health news, I find it reassuring to see the scientific community respond this quickly to a strain we were nearly starting from zero on.

What the clinical trial will actually test

Two compounds, four patient groups

According to reporting by Reuters and confirmed by the University of Minnesota's Center for Infectious Disease Research and Policy, the trial is a randomized platform trial that will evaluate the MBP134 monoclonal antibody, developed by Mapp Biopharmaceutical, alongside remdesivir, the Gilead Sciences antiviral already familiar to the public from its use against COVID-19.

In practice, patients will be split into four groups: one group will receive only MBP134, a second only remdesivir, a third will receive the combination of both, and a control group will receive the best available supportive care. Other treatments could be added over time if new scientific data justify it.

An international scientific partnership

The trial is coordinated by the DRC's National Institute for Biomedical Research, Belgium's Institute of Tropical Medicine, and the University of Oxford, with support from the WHO. This collaboration between Congolese, Belgian, and British researchers illustrates a dimension often forgotten in major health emergencies: the most effective response rarely comes from a single country acting alone.

According to Dr. Vasee Moorthy, acting head of WHO's R&D Blueprint group, this trial may need to enroll up to a thousand patients before yielding a definitive answer, a process that could stretch over several months, potentially into 2027. This honesty about the timeline strikes me as just as important as the trial itself: no one is promising a miracle in a few weeks, and that is exactly the tone needed when facing a disease this deadly.

The real scale of the outbreak on the ground

Ituri, the epicenter of a humanitarian crisis

The province of Ituri, in northeastern DRC, accounts for most of the virus's spread. According to the ECDC, it alone had 1,333 confirmed cases and 380 deaths, spread across 24 of the province's 36 health zones. The neighboring province of North Kivu reported 124 cases and 71 deaths, while South Kivu remained relatively spared with just three cases.

These figures tell only part of the story. The WHO itself describes the area as "densely populated" and marked by chronic insecurity, two factors that considerably complicate the work of contact-tracing and vaccination teams.

A health system under extreme strain

According to Reuters, capacity at Ebola treatment centers had already reached 650 beds, about 96% occupied at the time the trial launched. The WHO is actively working to add 300 more beds to meet rising demand, a considerable logistical effort in a region where road and medical infrastructure remain fragile.

The fatality rate observed in some areas, notably North Kivu where it reached 56.7% according to earlier CIDRAP data, is a reminder of how much every single day matters for care teams. These ground-level numbers, more than any official statement, show the real urgency behind this trial's launch.

The critical role of drug donations

Gilead and the United States open their reserves

Releasing drugs for this trial was never automatic. According to Reuters, the United States donated part of its MBP134 reserves, while Gilead Sciences announced it had supplied more than 2,000 additional vials of remdesivir for the clinical trial, on top of the 2,000 vials already donated in June for emergency compassionate use.

The WHO stated it is in discussions with both partners to ensure patients in the DRC can keep accessing these treatments after the trial, should they prove safe and effective. This is a point often overlooked in media coverage of this kind of announcement, yet it determines whether the research actually benefits the affected populations.

A lesson learned from previous crises

This push to secure post-trial access stems directly from criticism faced during earlier Ebola outbreaks, when promising treatments sometimes remained out of reach for local populations once clinical trials ended. Several organizations, including Public Citizen and AVAC, had publicly called as early as June for MBP134 to be made available more quickly. Seeing these lessons from the past concretely shape how treatment access is negotiated today strikes me as one of the rare tangible improvements in global health governance.

What these two compounds really represent

MBP134, an antibody born from a past epidemic

MBP134 is not a drug invented overnight. This monoclonal antibody cocktail was developed from antibodies taken from survivors of the 2014 West African outbreak, then initially engineered to target the Sudan strain of the virus with support from the U.S. agency BARDA. Its pan-ebolavirus potential — its ability to act against multiple strains of the virus — makes it a candidate researchers are watching closely.

This kind of reuse of earlier research illustrates a reality little known to the public: scientific advances made against one epidemic often become the foundation for responses to the next, even when the viral strain differs.

Remdesivir, between its COVID legacy and a new use

Remdesivir, for its part, is mostly known to the public for its use during the COVID-19 pandemic. According to CIDRAP, it had already shown in vitro activity against the Bundibugyo strain and had been used in earlier trials against the Zaire strain, notably as part of the PALM study. Neither drug, however, has yet been tested in humans specifically for treating Bundibugyo-type Ebola, which makes this trial all the more scientifically significant.

This absence of prior human data explains why the WHO is emphasizing methodological caution rather than hasty promises. I clearly prefer this rigorous approach over spectacular announcements that, historically, have often let down the populations most vulnerable to Ebola.

Testing: a link too often overlooked

A new test added to WHO's emergency list

The same day the clinical trial began, the WHO added the first diagnostic test for Bundibugyo Ebola virus to its emergency use listing, an essential regulatory step that speeds up the test's rollout in affected areas. Before this announcement, only one or two diagnostic tests were available for this specific strain, according to an emergency scientific consultation report published in late May.

This technical detail has very concrete consequences on the ground: the faster and more reliable the tests, the sooner infected patients can be isolated and treated, reducing the chances of transmission to those around them.

Contact tracing, an immense human challenge

According to ECDC data, roughly 82.7% of identified contacts remained under active monitoring in the Ituri and North Kivu provinces as of early July. That figure, while encouraging, hides a more complex reality: in certain areas, contact-tracing coverage was still described as "suboptimal" by the WHO itself, largely due to insecurity and the high mobility of local populations.

These operational difficulties are a reminder that medical technology, however promising, is never enough on its own to stop an outbreak of this scale. This may be the most important lesson of this crisis: a brilliant clinical trial is worth nothing without field teams capable of tracking every contact, every suspected case, every isolated village.

A spread that has already crossed borders

Cases exported to Europe and North America

The reach of this outbreak is no longer confined to Central Africa. According to the ECDC, an imported case was reported in France on June 24, 2026 by the health ministry, while an American citizen was medically evacuated to Germany for treatment. Both cases originated directly from the areas affected by the ongoing outbreak in the DRC.

Despite these exported cases, the ECDC maintains that the risk to populations in the European Union remains "very low," an assessment that will be revised if new data change the picture.

Uganda: a situation that appears to be stabilizing

In Uganda, the situation looks considerably more under control. According to the most recent data, the country had 20 confirmed cases and two deaths, with no new cases reported since June 21. Of the recorded cases, fifteen had a direct travel link to the DRC, and fifteen people in total had recovered.

This relative stabilization in Uganda stands in contrast to the still-rising trajectory seen on the Congolese side, where new health zones continue to be affected. I find this comparison between the two countries telling: it shows that a fast, well-coordinated response can genuinely slow the spread, even against a strain this poorly understood.

Funding, a blind spot too often forgotten

A funding shortfall documented from the earliest weeks

One month after the World Health Organization officially recognized the outbreak, Africa CDC was already publicly warning of a $21.5 million funding gap, deemed critical to sustaining contact-tracing efforts and medical supply chains. This kind of budget warning, far less dramatic than a clinical trial announcement, nonetheless determines very concretely whether field teams can contain the spread.

Africa CDC summed up the situation bluntly on social media, noting that the outbreak was "not yet under control" and that critical gaps remained in contact tracing and basic medical supplies.

An international mobilization that remains fragile

While drug donations like those from Gilead Sciences have grabbed media attention, funding for the day-to-day operations on the ground, often far less visible, remains just as decisive. Without trained staff, without fuel for tracing teams, without sufficient isolation capacity, even the most promising treatment cannot reach the patients who need it in time.

This budgetary reality is a reminder that responding to an outbreak rests on a fragile balance between scientific innovation and field logistics, two dimensions that must advance together to produce a real impact on the number of lives saved.

We talk a lot about the compounds and the laboratories, but rarely about that missing twenty-some million dollars on the ground; yet that is often exactly where the line falls between a contained outbreak and an uncontrolled spread.

Conclusion: measured hope, not an announced miracle

What this trial can actually change

The launch of this clinical trial does not mean the outbreak is nearing its end, nor that the 452 deaths already recorded will be the last. It does, however, represent a concrete scientific milestone after months during which medical teams on the ground had to make do with supportive care, with no targeted treatment against the Bundibugyo strain.

If the trial's results confirm the effectiveness of MBP134, remdesivir, or their combination, it will be the first time the medical community has a validated therapeutic tool specifically against this strain, with potential implications reaching well beyond the current outbreak alone.

Why caution is still warranted

The road ahead remains long. A trial that may need up to a thousand patients and could run for several months means definitive answers will not arrive before the current outbreak, one way or another, reaches its own conclusion. That is a difficult reality to accept, but it deserves to be stated plainly rather than dressed up as a premature victory.

What I choose to take from this week is a signal of measured hope: an international scientific community mobilized, concrete drug donations, and Congolese researchers at the heart of the effort rather than relegated to mere observers.

This is real progress, but fragile progress, one that will depend as much on scientific rigor as on the world's willingness not to look away before the trial delivers its results.

By Maxime Marquette, columnist

Columnist's transparency note

My sources and my limits

This editorial relies exclusively on public, verifiable sources, including the World Health Organization, Reuters, the Center for Infectious Disease Research and Policy, and the European Centre for Disease Prevention and Control, all cited in full at the end of this text. I have no direct access to the ground in the Democratic Republic of Congo or to confidential clinical data from the ongoing trial.

I have no professional or financial ties to the World Health Organization, Mapp Biopharmaceutical, Gilead Sciences, or the research institutions mentioned in this piece.

What I don't know

I don't know whether MBP134 or remdesivir will prove effective against the Bundibugyo strain, nor how long the clinical trial will actually take to deliver definitive results. These scientific uncertainties are at the very heart of why this trial exists, and I would rather name them than speculate.

Sources

Primary sources

World Health Organization — Ebola outbreak - DRC 2026 — July 2, 2026

Reuters — Trial for Bundibugyo Ebola treatment starts in DRC, WHO says — July 2, 2026

European Centre for Disease Prevention and Control — Ebola disease outbreak in the DRC and Uganda — July 3, 2026

Secondary sources

CIDRAP — Clinical trial for Ebola therapies begins in DR Congo — July 2, 2026

BBC — Ebola treatments trial begins in the Democratic Republic of Congo — July 3, 2026

CIDRAP — Experts urge use of experimental antibodies in DR Congo to combat Ebola — June 17, 2026